Search 

Prior to joining the NRC, Dr.Houle had spent 14 years leading business, corporate and product development activities in private and public biotechnology firms at various stages of development from University spin-offs to more established companies. Most recently, as COO of Kapplex, he guided the company through its initial spin-out of the University into a full-fledged funded start-up. Prior to Kapplex, Dr. Houle held a leadership role in product and business development at Axela, a company in the field of multiplexed biomarker detection, leading the successful launch of several products. Dr. Houle began his industrial career at SYNX Pharma, a proteomics and diagnostics company, where he sought out, structured and fostered collaborations and alliances. These activities led to a diagnostic development agreement with Ortho-Clinical Diagnostics and the eventual merger of SYNX with Nanogen Inc. JF holds a Ph.D. in Experimental Medicine from McGill University and holds several patents in the field of biomarker detection.